NCT05066022View on ClinicalTrials.gov

A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

NAUnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

August 30, 2022

Study Completion Date

July 29, 2024

Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
BIOLOGICAL

CT0590 CAR T Cells

Dose-escalated CAR T cells infusion

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital of Soochow University

OTHER